Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Evolocumab
Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial
Posted inClinical Updates Wellness & Lifestyle

Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial

Posted by By MedXY 08/17/2025
Evolocumab significantly lowers LDL cholesterol and substantially reduces cardiovascular events in patients with autoimmune/inflammatory diseases alongside statin therapy, according to the FOURIER trial analysis.
Read More
  • Debunking Weight Loss Myths: Avoid These Pitfalls for More Effective and Healthy Weight Loss
  • Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss
  • Mastering the Art of Running: Scientific Guide to Safe and Effective Running
  • The Rise of Healthy Running: A Scientific Approach to Fitness
  • Valve Underexpansion in ACURATE neo2 TAVR: Implications for Clinical Outcomes and Future Directions
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

AI Alzheimer's disease artificial intelligence blood pressure breast cancer cardiovascular health cardiovascular risk clinical trial clinical trials COPD Dementia diabetes diet dinh dưỡng exercise health healthcare heart failure HFpEF HIV Hypertension immunotherapy longevity MASLD men's health mental health NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial sexual health sleep stroke sức khỏe sức khỏe tình dục treatment type 2 diabetes weight loss wellness women's health 肥満

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top